Maruyama Michio, Ebuchi Masakazu, Takashima Kaku, Maruyama Shoji, Hasegawa Kumi, Ohbe Masahide, Koide Ayaki, Shinoura You, Katoh Kiyomi
Dept. of Surgery, Tokyo Metropolitan Ohkubo Hospital.
Gan To Kagaku Ryoho. 2004 Oct;31(11):1714-6.
We studied the efficacy of MTX/CDDP/5-FU intra-peritoneal chemotherapy for advanced and metastatic gastric cancer (n=24), and compared the results with intra-aortic (n=26) and intra-venous (n=21) routes of MTX-CDDP-5-FU double modulation therapy. I.p. administration was more efficient for reduction of malignant acites (p=0.049). However, median survival duration of malignant acites cases showed no difference between the i.p. group and i.a., i.v. groups (p=0.103). Survival rate of the i.p. group was no different with those of i.a. and i.v. groups (p=0.36). Frequency of side effects is much lower in the i.p. group.
我们研究了甲氨蝶呤/顺铂/5-氟尿嘧啶腹腔内化疗对晚期和转移性胃癌(n = 24)的疗效,并将结果与甲氨蝶呤-顺铂-5-氟尿嘧啶双药联合疗法的主动脉内给药(n = 26)和静脉内给药(n = 21)途径进行了比较。腹腔内给药在减少恶性腹水方面更有效(p = 0.049)。然而,恶性腹水病例的中位生存期在腹腔内给药组与主动脉内给药组、静脉内给药组之间无差异(p = 0.103)。腹腔内给药组的生存率与主动脉内给药组和静脉内给药组的生存率无差异(p = 0.36)。腹腔内给药组的副作用发生率低得多。